October 1, 2024 The AMR Accelerator Calls to Action: European Capacity for Antibiotic R&D Requires Long-term Funding Note: You are reading this information because Critical Path Institute is a partner of both ERA4TB and Unite4TB.
September 30, 2024 C-Path to Lead Comprehensive Task Force Focused on Accelerating Drug Development for Limb-Girdle Muscular Dystrophies C-Path announced the formation of a new task for under its RDCA-DAP, dedicated to...
September 30, 2024 TNF-α inhibitors for type 1 diabetes: exploring the path to a pivotal clinical trial Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction...
September 27, 2024 Conceptualizing meaningful between-group difference in change over time: a demonstration of possible viewpoints Purpose Determining if group-level differences in health outcomes are meaningful has recently been neglected...
September 26, 2024-September 27, 2024 2024 Complex In Vitro Model: Qualification Framework Public Workshop Critical Path Institute’s (C-Path) Predictive Safety Testing Consortium (PSTC) is delighted to announce the second...
September 19, 2024 C-Path’s PKD Outcomes Consortium Receives BAA Award for Project to Advance Drug Development Tools for Autosomal Dominant Tubulointerstitial Kidney Disease C-Path is thrilled to announce its PKDOC has been awarded...
September 12, 2024 C-Path’s Inaugural Global Impact Conference Charts the Future of Drug Development C-Path successfully concluded its inaugural Global Impact Conference (CGIC) on September 11, 2024.
September 12, 2024 Steve Gleason Welcomes Guests to Day 2 of #CGIC24 Former NFL player and ALS patient advocate welcomes attendees to the second day of C-Path’s Global Impact Conference.
September 9, 2024-September 11, 2024 C-Path Hosts its Inaugural Global Impact Conference We are thrilled to invite you to the inaugural Critical Path Institute Global Impact Conference taking place this September...
September 9, 2024 FDA Issues ‘Letter of Support’ Encouraging Use of Synuclein-based Biomarker, αSyn-SAA, in Clinical Trials in Parkinson’s and Related Diseases FDA) encouraged scientists and drug developers to use the alpha-synuclein seed amplification assay (αSyn-SAA) biomarker...
